New treatment for severe inflammation caused by respiratory infections
Treatment of Inflammatory Complications of Respiratory Infection
['FUNDING_OTHER'] · RESPANA THERAPEUTICS, INC. · NIH-10900757
This study is testing a new treatment called RT-002, which is designed to help people with severe inflammation caused by respiratory infections, and it aims to find out how well it works and if it's safe for future use in humans.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESPANA THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10900757 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel therapeutic monoclonal antibody, RT-002, aimed at treating severe inflammatory complications that arise from acute respiratory infections. The approach involves targeting a specific receptor, SP-R210, which may provide effective treatment regardless of the pathogen involved. The research includes rigorous testing in mouse models to assess the safety and efficacy of RT-002, with the goal of advancing it toward clinical trials for human patients. By understanding how RT-002 interacts with human immune cells, the research aims to design a treatment that can effectively manage harmful immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults and older individuals experiencing severe inflammatory responses due to acute respiratory infections.
Not a fit: Patients with mild respiratory infections or those who do not experience significant inflammatory complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly reduces mortality and improves lung health in patients suffering from severe respiratory infections.
How similar studies have performed: While the approach of targeting host-mediated pathways is promising, this specific monoclonal antibody treatment is novel and has not been extensively tested in human clinical trials yet.
Where this research is happening
PHILADELPHIA, UNITED STATES
- RESPANA THERAPEUTICS, INC. — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LARK, MICHAEL WILLIAM — RESPANA THERAPEUTICS, INC.
- Study coordinator: LARK, MICHAEL WILLIAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Airway infections